Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, As A Single Agent And In Combination With Either PF-06801591 Or Lenalidomide In Relapse/ Refractory Multiple Myeloma

  • Interventional
  • Recruiting
  • NCT03269136
Eligibility Details Visit Clinicaltrials.gov

A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF PF-06863135, A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH EITHER PF-06801591 OR LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Study C1071001 is a Phase 1, open label, multi dose, multi center, dose escalation, safety, pharmacokinetic (PK) and pharmacodynamic study of PF-06863135 in adult patients with advanced multiple myeloma who have relapsed from or are refractory to standard therapy. This two part study will assess the safety and tolerability of increasing dose levels of PF-06863135 in Part 1, and establish the recommended Phase 2 dose (RP2D) in Part 2.

Gender
All

Age Group
18 Years and up

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         - Relapsed/refractory multiple myeloma

         - Progressed or are intolerant of established therapies including proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody

         - Performance Status of 0- 2 (unless due to bone pain)

         - Adequate bone marrow, hematological, kidney and liver function

         - Resolved acute effects of any prior therapy to baseline severity

         - Not pregnant

        Exclusion Criteria:

         - Recent history of other malignancies

         - History of active autoimmune disorders

         - Any form of primary immunodeficiency

         - Active and clinically significant bacterial, fungal, or viral infection

         - Evidence of active mucosal or internal bleeding

         - History of severe immune-mediated adverse event with prior immunomodulatory treatment

         - Major surgery within 4 weeks of study treatment start

         - Radiation therapy within 2 weeks of study treatment start

         - History of stem cell transplant (autologous or allogeneic) within 100 days prior to study enrollment

         - Donor Lymphocyte Infusion (DLI) within 30 days prior to study entry

         - Less than 30 days since last dose of antibody based therapies or less than 5 half-lives since last dose of previous therapy

         - Requirement for systemic immune suppressive medication

         - Current requirement for chronic blood product support

At a Glance

National Government IDNCT03269136

IRB#IRB17-1082

Lead SponsorPfizer

Lead PhysicianAndrzej Jakubowiak

Collaborator(s)N/A

EligibilityAll
18 Years and up
Recruiting